<DOC>
	<DOCNO>NCT00015834</DOCNO>
	<brief_summary>Phase I/II trial study effectiveness combine STI571 chemotherapy treat patient chronic myelogenous leukemia . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . STI571 may stop growth leukemia cell . Combining chemotherapy STI571 may kill cancer cell</brief_summary>
	<brief_title>STI571 Plus Cytarabine Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose high-dose cytarabine combine imatinib mesylate patient blastic phase chronic myelogenous leukemia . II . Determine safety regimen patient . III . Determine pharmacokinetics regimen patient . IV . Determine frequency hematologic cytogenetic response , duration response , survival patient treat regimen . OUTLINE : This multicenter , dose-escalation study cytarabine . Phase I : Patients previously receive imatinib mesylate receive oral imatinib mesylate daily day 1-35 . Patients previously receive imatinib mesylate least 28 day receive oral imatinib mesylate day 22-35 . All patient receive cytarabine IV 2 hour every 12 hour day 29-32 . Patients 5 % residual blast bone marrow day 28 receive second course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos cytarabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Phase II : Additional patient treat dose level precede MTD . Patients follow monthly .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Diagnosis chronic myelogenous leukemia myeloid blast crisis At least 30 % blast bone marrow Philadelphia chromosome positive cytogenetic analysis bcr/abl translocation fluorescent situ hybridization Ineligible refuse allogeneic stem cell transplantation Not previously treat imatinib mesylate OR currently receive imatinib mesylate stable disease 2 bone marrow biopsy least 2 week apart Performance status ECOG 02 See Disease Characteristics Bilirubin less 3 time upper limit normal ( ULN ) AST ALT less 3 time ULN Creatinine less 2 time ULN No New York Heart Association class III IV heart disease Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 2 week study female patient least 3 month study male patient See Disease Characteristics No prior allogeneic bone marrow peripheral blood stem cell transplantation At least 48 hour since prior interferon alfa At least 24 hour since prior hydroxyurea At least 6 week since prior busulfan No prior chemotherapy blast crisis ( except hydroxyurea ) Concurrent hydroxyurea anagrelide severe leukocytosis thrombocytosis allow At least 4 week since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>